

FOI REF: 21/476

20<sup>th</sup> September 2021

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1. **In the past three months, how many patients were treated for Triple-Negative Breast Cancer with the following:**

a) Anthracycline (eg doxorubicin) as a single agent	0
b) Atezolizumab + nab-paclitaxel or paclitaxel	0
c) Capecitabine as a single agent	0
d) Eribulin as a single agent	0
e) Eribulin + other chemotherapy	0
f) PARP inhibitor (eg Olaparib)	0
g) Platinum (eg carboplatin, cisplatin) as a single agent	0
h) Taxane (eg docetaxel, paclitaxel, nab-paclitaxel) as a single agent	1
i) Other single agent chemotherapy	0
j) Other chemotherapy combination	0
k) Other immunotherapy containing regimen	0
l) Other active systemic anti-cancer therapy	0
  
1. **How many of these Triple-Negative Breast Cancer patients treated in the last three months received treatment that was:**

a) Privately funded	0
b) Part of clinical trial	0
c) Part of an early access scheme	0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)  
Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)